WHO study finds remdesivir and hydroxychloroquine ineffective against covid-19

0
1
WHO study finds remdesivir and hydroxychloroquine ineffective against covid-19




Study shows that medications had little or no influence in reducing disease mortality or length of hospital stay


© Marco Santos / Pará Agency
Study shows that drugs had little or no influence in reducing the mortality of the disease or the length of hospital stay of patients

The WHO (World Health Organization) released this Thursday (15.out.2020) the previous results of a global study carried out in 405 hospitals in more than 30 countries. Research shows that 4 antivirals used to treat covid-19 are ineffective. Are they:

  • remdesivir;
  • hidroxicloroquina;
  • lopinavir / ritonavir (combination); and
  • interferon beta-1a.

The study “Solidarity Therapeutics Trial” (whole – 2 MB) awaits approval of scientific journals and review by other experts.

11,266 adults participated in the study. Of these, 2,750 took remdesivir; 954 took hydroxychloroquine; 1,411 took lopinavir; 651, interferon and lopinavir; 1,412 took only interferon; and 4,088 were part of the control group, which received none of the drugs.

The evidence points out that the drugs had little or no influence in reducing the mortality from the disease. WHO also points out that there is no evidence that any of the drugs “significantly reduced recovery time or hospital stay for patients“.

For each drug in the study, the effect on mortality was disappointingly not very promising“Said the WHO.

Despite having enthusiasts – like President Jair Bolsonaro -, hydroxychloroquine had already been excluded from covid-19 treatment protocols by many countries. Remdesivir, on the other hand, is still seen as an effective medicine to fight the disease. The drug became the 1st to be authorized by the European Union to treat coronavirus infection. The antiviral, originally used against Ebola, was 1 of those used by the US president, Donald Trump, for treatment.

Gilead Sciences, maker of remdesivir, said in a note (whole – 196 KB), that the results of WHO studies “seem inconsistent with more robust evidence from multiple controlled studies published in reviewed journals that validate the clinical benefit”Of the medicine.

“We are concerned that the data in this global open label trial have not been subjected to the rigorous review required to allow constructive scientific discussion.”

LEAVE A REPLY

Please enter your comment!
Please enter your name here